نتایج جستجو برای: ntravitreal bevacizumab

تعداد نتایج: 11193  

2017
Yeoun-Hee Kim Jae-Chang Jung Sang Il Gum Su-Bin Park Jin Yeul Ma Yong Il Kim Kyoo Won Lee Young Jeung Park

We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used ...

2011
Marc C. Chamberlain

Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy,...

Journal: :Oncology 2010
Volker Heinemann Paulo M Hoff

OBJECTIVES Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in combination with standard chemotherapy. This review describes the evolution of irinotecan-based regimens for metastatic colorectal cancer and eval...

2013
Saurabh Luthra Ashish Sharma Joyce Dong Aneesh Neekhra Ana L Gramajo Gail M Seigel M Cristina Kenney Baruch D Kuppermann

PURPOSE To evaluate the effect of bevacizumab on the mitochondrial function of human retinal pigment epithelial (ARPE-19), rat neurosensory retinal (R28) and human microvascular endothelial (HMVEC) cells in culture. MATERIALS AND METHODS ARPE-19 and R28 cells were treated with 0.125, 0.25, 0.50 and 1 mg/ml of bevacizumab. The HMVEC cultures were treated with 0.125, 0.25, 0.50 and 1 mg/ml of b...

2014
Idris Bahce Marc C Huisman Eline E Verwer Rogier Ooijevaar Firdaouss Boutkourt Danielle J Vugts Guus AMS van Dongen Ronald Boellaard Egbert F Smit

BACKGROUND The aim of this pilot study was to evaluate whether the uptake of (89)Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor (89)Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. METHODS Seven NSCLC patients underwent static PET scans at days 4 and 7 aft...

Journal: :The New England journal of medicine 2014
Mark R Gilbert James J Dignam Terri S Armstrong Jeffrey S Wefel Deborah T Blumenthal Michael A Vogelbaum Howard Colman Arnab Chakravarti Stephanie Pugh Minhee Won Robert Jeraj Paul D Brown Kurt A Jaeckle David Schiff Volker W Stieber David G Brachman Maria Werner-Wasik Ivo W Tremont-Lukats Erik P Sulman Kenneth D Aldape Walter J Curran Minesh P Mehta

BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with n...

Journal: :Clinical colorectal cancer 2013
Veena Shankaran David Mummy Lisel Koepl David Blough Yeun Mi Yim Elaine Yu Scott Ramsey

BACKGROUND The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS Patients age ≥65 were identified from SEER-Medicare and categorized by mCRC diagnosis pre and post bevacizumab approval (2001-2003 vs. 2005-200...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
David C Turner Fariba Navid Najat C Daw Shenghua Mao Jianrong Wu Victor M Santana Michael Neel Bhaskar Rao Jennifer Reikes Willert David M Loeb K Elaine Harstead Stacy L Throm Burgess B Freeman Clinton F Stewart

PURPOSE To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing outcomes. EXPERIMENTAL DESIGN Before tumor resection, three doses of bevacizumab (15 mg/kg) were administered to patients (median age, 12.2 years) enrolled in a multi-institutional osteosarcoma trial....

2013
Hirokazu Taniguchi Tomoko Tsuchida Yoichi Nakamura Kohei Motoshima Kosuke Mizoguchi Shigeru Kohno

Bevacizumab has a lower risk of treatment-related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year-old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung di...

2015
Daniel Escorsim Machado Jamila Alessandra Perini Margarida Maria Camoes Orlando Ralph Santos-Oliveira

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید